Servier Brand Guidelines: An Orléans Lab of 1954, a Foundation Owner & Mediator

Ten people and a small firm on the Loire.

Servier began in Orléans, on the Loire, in 1954. French Wikipedia says the laboratory was created that year by Jacques Servier and nine other people, who bought a business that made syrups. A year later the firm launched its first two products, a medicine for high blood pressure and one for diabetes, and it grew, the same article says, mainly through its own research.

The 1960s brought new molecules. French Wikipedia says the laboratories put fenfluramine and benfluorex on the market in that decade; benfluorex, sold as Mediator, received its French marketing authorisation in 1974. A cough medicine based on fenspiride followed in 1973. By 1989, French Wikipedia says, Servier’s research and development centre counted about 1,000 researchers.

French Wikipedia names cardio-metabolism, venous diseases, neurology and cancer as its research areas. English Wikipedia lists among its notable products Coversyl, a perindopril medicine for blood pressure, Diamicron, a gliclazide medicine for diabetes, Procoralan, an ivabradine medicine, and Vastarel; French Wikipedia says Servier introduced Procoralan in 2005 and that Coversyl was among the most-sold medicines in France in 2007. French Wikipedia also lists the venous medicine Daflon among its medicines in France.

The company spread abroad early. French Wikipedia says Servier took a majority of the Hungarian drug maker Egis in 1995 and announced in September 2013 that it was buying the remaining shares. French Wikipedia says the group is present in about 140 countries and that more than nine in ten Servier medicines are used outside France.

A foundation instead of shareholders.

Servier’s ownership is unusual. French Wikipedia says the group is governed by a foundation under Dutch law, the Fondation internationale de recherche Servier, or FIRS, which has no capital and is non-profit, and which has the power to appoint and dismiss the group’s managers. English Wikipedia likewise describes Servier as governed by a non-profit foundation.

The structure was designed by the founder. French Wikipedia says Jacques Servier created the foundation and transferred his company’s capital to it to secure its future independence, and that the legal arrangement was put in place at the end of the 1990s to separate governance from capital. The holding company, Servier SAS, which owns all the group’s companies, is held by three associations and by companies it controls itself, with no individual among its shareholders. A foundation board and an executive committee run the foundation; at the end of April 2014 Olivier Laureau, the group’s finance chief, became president of the foundation and of the group, French Wikipedia says.

The headquarters is in Suresnes, west of Paris. French Wikipedia lists six research centres, three of them in France including one at Paris-Saclay, and one each in Denmark, Hungary and the United States. English Wikipedia says the Servier clinical support unit at Gidy near Orléans makes medicines for clinical trials, and French Wikipedia says Servier inaugurated its first unit for producing biological medicines at Gidy in November 2024.

Cancer medicine has grown since 2018. Both Wikipedias say Servier bought the oncology business of Shire in 2018, with a US base in Boston, and French Wikipedia says it announced the purchase of the oncology business of Agios Pharmaceuticals in December 2020; English Wikipedia adds that Servier acquired Symphogen in 2020.

How mid-sized drug makers present themselves.

Europe’s mid-sized drug makers tend to present themselves through their origins. Many began as a single pharmacist, doctor or industrialist with a laboratory, and their corporate histories still open with a founder, a town and a first product. Family holding companies and foundations often remain in the background as long-term shareholders, and the companies’ own timelines give as much space to new factories and research centres as to the medicines that came out of them.

The visual language that follows is restrained. Corporate sites and annual reports favour photographs of scientists at the bench, production lines seen through glass, and patients in ordinary settings — at home, at work, outdoors — rather than in hospital. Long-serving research campuses, some in use for half a century or more, appear again and again as proof of continuity, alongside newer laboratories in biotech districts abroad.

Identity systems are usually simple: a short word mark or set of initials, a single deep blue or green as the lead colour, and a clean sans for running text. Because prescription medicines cannot be advertised to the general public in the European Union, much of the visible branding lives at medical congresses rather than in shop windows: the dermatology meeting of the EADV, the multiple sclerosis congress of ECTRIMS and the reproductive-medicine meeting of ESHRE are among the places where these companies set up stands, posters and symposia for specialists.

This guide sets out what can be checked about each company — who founded it, who owns it, where it makes and researches its medicines, and how its history is told — and marks plainly what rests only on the company’s own word. The palettes and typefaces shown here are our own interpretations, not official brand assets.

The Mediator case and a generics sale.

The Mediator case is part of Servier’s public record. French Wikipedia says the benfluorex medicine was sold in France from 1976 until it was banned in November 2009. On 29 March 2021 the court in Paris convicted Servier of aggravated deception and of involuntary manslaughter and injury and fined the company, while acquitting it of fraud and of improperly obtaining its marketing authorisation; the French medicines agency was also fined. Both the prosecution and Servier appealed, and the appeal trial opened in January 2023. In late December 2023, the medical journal Prescrire International reported in December 2024, the Paris appeal court found Servier guilty of all the offences it was charged with, including fraud and improperly obtaining and renewing the marketing authorisation, and French Wikipedia says the fine was increased.

The company has also reshaped its business. Servier long owned the French generics maker Biogaran. French Wikipedia says an attempt to sell it failed in 2024 and that Servier relaunched the sale in the summer of 2025. On 2 February 2026 Le Quotidien du Pharmacien reported that the sale was complete, with the French public bank Bpifrance as a minority shareholder, and the business news site InforCapital reported the same day that the investment firm BC Partners and Bpifrance had closed their purchase of Biogaran, after its staff committee gave a favourable opinion in October 2025, and that the buyers had committed to keep its headquarters in France.

Servier’s other ventures include WeHealth, an e-health branch launched in 2016, French Wikipedia says, and a research partnership with BioLabs for an incubator at Paris-Saclay announced in June 2021.

For a design guide, Servier shows how a company owned by a foundation rather than by shareholders presents a long record — research campuses, heart medicines, a court case and a recent sale — under one family name. Compare Sanofi, the larger French drug maker, and Pierre Fabre, another French drug maker that carries its founder’s name. For this guide we use a deep blue, a limestone neutral and an amber with a serif, an unofficial interpretation; no product or logo is reproduced.

Keep Servier’s identity on hand — save it to a board in the Made Good inspiration library.